To further explore the role of MC1R in nephrotic disease, the highly selective, synthetic, and stable agonist BMS-470539, and the unselective MCR agonist α-MSH were used for treating adriamycin-induced nephropathy (Figure 2B). Here, NR3C2 is linked to Nephropathy.